Modulators of 14-3-3 Protein-Protein Interactions
Top Cited Papers
Open Access
- 9 May 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (9), 3755-3778
- https://doi.org/10.1021/acs.jmedchem.7b00574
Abstract
Direct interactions between proteins are essential for the regulation of their functions in biological pathways. Targeting the complex network of protein protein interactions (PPIs) has now been widely recognized as an attractive means to therapeutically intervene in disease states. Even though this is a challenging endeavor and PPIs have long been regarded as "undruggable" targets, the last two decades have seen an increasing number of successful examples of PPI modulators, resulting in growing interest in this field. PPI modulation requires novel approaches and the integrated efforts of multiple disciplines to be a fruitful strategy. This perspective focuses on the hub-protein 14-3-3, which has several hundred identified protein interaction partners, and is therefore involved in a wide range of cellular processes and diseases. Here, we aim to provide an integrated overview of the approaches explored for the modulation of 14-3-3 PPIs and review the examples resulting from these efforts in both inhibiting and stabilizing specific 14-3-3 protein complexes by small molecules, peptide mimetics, and natural products.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (CRC 1093)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024.001.035, 016.150.366)
This publication has 166 references indexed in Scilit:
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- Synthesis of a Phosphoserine Mimetic Prodrug with Potent 14-3-3 Protein Inhibitory ActivityCell Chemical Biology, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Proteomic comparison of four Eimeria tenella life‐cycle stages: Unsporulated oocyst, sporulated oocyst, sporozoite and second‐generation merozoiteProteomics, 2009
- The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer developmentTrends in Cell Biology, 2009
- An empirical framework for binary interactome mappingNature Methods, 2008
- How many drug targets are there?Nature Reviews Drug Discovery, 2006